Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bruker Daltonics

This article was originally published in The Gray Sheet

Executive Summary

Firm goes public Aug. 4 via initial offering of 8 mil. shares at $13 each under the Nasdaq symbol "BDAL." The Billerica, Massachusetts maker of mass spectrometry life science tools plans to use gross proceeds of $104 mil. for the expansion of sales and marketing capabilities, R&D, debt repayment, working capital, potential acquisitions and other general corporate purposes. UBS Warburg LLC is the lead manager for the offering, with CIBC World Markets and Thomas Weisel Partners LLC co-managing. The underwriters hold an over-allotment option of 1.2 mil. additional shares

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel